Novel Technologies And Clinical Pipeline Will Unlock Future Possibilities

Shared on01 May 25
Fair value Increased 4.17%

Shared on24 Apr 25
Fair value Decreased 7.37%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 3.64%

AnalystConsensusTarget has decreased revenue growth from 29.5% to 26.1% and increased future PE multiple from 170.5x to 205.8x.